Onorach Ltd-製薬・医療分野:企業M&A・提携分析

◆英語タイトル:Onorach Ltd - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA8014289
◆発行会社(調査会社):GlobalData
◆発行日:2017年11月22日
◆ページ数:46
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:イギリス
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single UserUSD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Onorach Ltd (Onorach) is a contract research organization that provides clinical support services. The organization service portfolio includes tailored clinical trial support, clinical plan development, protocol design, regulatory, quality management, clinical operations management, patient and subject recruitment, project management, clinical monitoring, statistical analysis and medical report writing services among others. Onorach also provides temperature monitoring, stability testing, drug supplying, placebo sourcing, labeling, packaging, distribution, and pre-clinical and specialized lipid analysis services. The organization’s target therapy areas include cardiovascular, cell based therapeutics, CNS, neurology, endocrinology, infectious diseases, oncology, pediatricians, women’s health, and other therapeutics areas. It caters to pharmaceutical, biotech and medical device companies. Onorach is headquartered in Dundee, the UK.

Onorach Ltd – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Onorach Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6
Onorach Ltd, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 7
Onorach Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8
Onorach Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 9
Onorach Ltd, Medical Devices Deals, 2011 to YTD 2017 10
Onorach Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 11
Onorach Ltd, Pharmaceuticals & Healthcare, Deal Details 13
Venture Financing 13
Epirus Biopharma Raises US$36 Million In Series B Venture Financing 13
EPIRUS Biopharmaceuticals Secures USD5 Million in Venture Funding 15
EPIRUS Biopharmaceuticals Secures USD8.08 Million in Venture Funding 16
Private Equity 17
BioGeneration Ventures, Thuja Capital and Forbion Capital Partners Divest Bioceros 17
Partnerships 18
Polpharma Enters into Agreement with Epirus Biopharma 18
EPIRUS Biopharma Enters into Distribution Agreement with mAbxience 19
Epirus Enters Into Co-Development Agreement With Orygen Biotecnologia 20
Zalicus And Hydra Biosciences Enter Into Partnership To Develop Ion Channel Product Candidates For Treatment Of Pain 21
Licensing Agreements 22
Livzon Mabpharm Amends its Licensing Agreement with Epirus Biopharma 22
Zalicus Enters into Licensing Agreement with AnaBios for Sodium Channel Pain Modulation Program 24
Epirus Enters Into Licensing Agreement With Ranbaxy Labs For BOW015 25
Zalicus Extends Licensing Agreement With Novartis Institutes For Oncology Combinations 26
Bioceros Expands Licensing Agreement With Crucell 27
Zalicus Extends Licensing Agreement With Novartis Institutes for BioMedical Research 28
Equity Offering 29
Epirus Biopharma to Raise up to USD30 Million in Public Offering of Shares 29
Epirus Biopharma Raises USD53 Million in Public Offering of Shares 30
Zalicus Completes First Tranche Of Private Placement Of Shares For US$2 Million 31
Zalicus Completes Public Offering Of Shares For US$15 Million 32
Zalicus Completes Second Tranche Of Private Placement Of Shares For US$9 Million 33
Zalicus Completes Second Tranche Of Private Placement Of Shares For US$4.25 Million 34
Asset Transactions 35
Reliance Life Sciences Acquires Global Rights of Infliximab from EPIRUS Biopharma 35
Horizon Discovery Completes Acquisition of Combination High Throughput Screening from Zalicus 36
Acquisition 37
Polpharma to Acquire EPIRUS Netherlands from EPIRUS Biopharma 37
Taro Pharma Acquires Zalicus Pharma 39
Epirus Biopharma Acquires Bioceros for USD14 Million 40
Epirus Biopharma Acquires Zalicus in Reverse Takeover Transaction 41
Onorach Ltd – Key Competitors 43
Onorach Ltd – Key Employees 44
Onorach Ltd – Locations And Subsidiaries 45
Head Office 45
Other Locations & Subsidiaries 45
Appendix 46
Methodology 46
About GlobalData 46
Contact Us 46
Disclaimer 46

List of Tables
Onorach Ltd, Pharmaceuticals & Healthcare, Key Facts 2
Onorach Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6
Onorach Ltd, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 7
Onorach Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8
Onorach Ltd, Deals By Therapy Area, 2011 to YTD 2017 9
Onorach Ltd, Medical Devices Deals, 2011 to YTD 2017 10
Onorach Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 11
Epirus Biopharma Raises US$36 Million In Series B Venture Financing 13
EPIRUS Biopharmaceuticals Secures USD5 Million in Venture Funding 15
EPIRUS Biopharmaceuticals Secures USD8.08 Million in Venture Funding 16
BioGeneration Ventures, Thuja Capital and Forbion Capital Partners Divest Bioceros 17
Polpharma Enters into Agreement with Epirus Biopharma 18
EPIRUS Biopharma Enters into Distribution Agreement with mAbxience 19
Epirus Enters Into Co-Development Agreement With Orygen Biotecnologia 20
Zalicus And Hydra Biosciences Enter Into Partnership To Develop Ion Channel Product Candidates For Treatment Of Pain 21
Livzon Mabpharm Amends its Licensing Agreement with Epirus Biopharma 22
Zalicus Enters into Licensing Agreement with AnaBios for Sodium Channel Pain Modulation Program 24
Epirus Enters Into Licensing Agreement With Ranbaxy Labs For BOW015 25
Zalicus Extends Licensing Agreement With Novartis Institutes For Oncology Combinations 26
Bioceros Expands Licensing Agreement With Crucell 27
Zalicus Extends Licensing Agreement With Novartis Institutes for BioMedical Research 28
Epirus Biopharma to Raise up to USD30 Million in Public Offering of Shares 29
Epirus Biopharma Raises USD53 Million in Public Offering of Shares 30
Zalicus Completes First Tranche Of Private Placement Of Shares For US$2 Million 31
Zalicus Completes Public Offering Of Shares For US$15 Million 32
Zalicus Completes Second Tranche Of Private Placement Of Shares For US$9 Million 33
Zalicus Completes Second Tranche Of Private Placement Of Shares For US$4.25 Million 34
Reliance Life Sciences Acquires Global Rights of Infliximab from EPIRUS Biopharma 35
Horizon Discovery Completes Acquisition of Combination High Throughput Screening from Zalicus 36
Polpharma to Acquire EPIRUS Netherlands from EPIRUS Biopharma 37
Taro Pharma Acquires Zalicus Pharma 39
Epirus Biopharma Acquires Bioceros for USD14 Million 40
Epirus Biopharma Acquires Zalicus in Reverse Takeover Transaction 41
Onorach Ltd, Key Competitors 43
Onorach Ltd, Key Employees 44
Onorach Ltd, Subsidiaries 45

★海外企業調査レポート[Onorach Ltd-製薬・医療分野:企業M&A・提携分析]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Curemark LLC-医療機器分野:企業M&A・提携分析
    Summary Curemark LLC (Curemark) is a biopharmaceutical company that offers development of novel therapies. The company develops novel therapies to treat serious diseases for which there are limited treatment options. It provides CM-AT, CM-4612, CM-PK, CM-182, and CM-1212 drugs. Curemark’s product ca …
  • Antitope Ltd:企業のM&A・事業提携・投資動向
    Antitope Ltd - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Antitope Ltd Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), divestments, …
  • Omaxe Ltd:企業の戦略・SWOT・財務情報
    Omaxe Ltd - Strategy, SWOT and Corporate Finance Report Summary Omaxe Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actions …
  • Kodiak Sciences Inc:製薬・医療:M&Aディール及び事業提携情報
    Summary Kodiak Sciences Inc (Kodiak Sciences), formerly Oligasis LLC is a drug development company that discovers new medicines for the healthcare sector. The company provides retinal medicines for treatment of wet and dry forms of age-related macular degeneration. It utilizes proprietary Bioconjuga …
  • Elcelyx Therapeutics Inc:製薬・医療:M&Aディール及び事業提携情報
    Summary Elcelyx Therapeutics Inc (Elcelyx) is a developer of novel therapies for the treatment of type 2 diabetes, kidney disease and limb amputation. The company develops drugs that regulate the gut neuroendocrine system including the L-cell, which assists in the release of glucoregulatory hormones …
  • Viterra Inc.:企業の戦略・SWOT・財務分析
    Viterra Inc. - Strategy, SWOT and Corporate Finance Report Summary Viterra Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate a …
  • Genedrive Plc (GDR):企業の製品パイプライン分析
    Summary Genedrive Plc (Genedrive), formerly Epistem Holdings plc, develops and markets point of need molecular diagnostics platform for identifying infectious diseases and pathogens and providing other indications. The Genedrive HCVID test is the company’s CE-IVD certified molecular diagnostics plat …
  • MSCI Inc. (MSCI):企業の財務・戦略的SWOT分析
    MSCI Inc. (MSCI) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the …
  • Koninklijke Philips N.V. (PHIA)-エネルギー分野:企業M&A・提携分析
    Summary Koninklijke Philips N.V. (Philips) is a diversified technology company which focuses on improving people’s health and enabling better outcomes across the health continuum from healthy living and prevention, to diagnosis, treatment and home care. The company develops and manufactures medical …
  • CRH plc:企業のM&A・事業提携・投資動向
    CRH plc - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's CRH plc Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), divestments, capital ra …
  • Duke Energy Carolinas LLC:企業の発電所・SWOT分析2018
    Duke Energy Carolinas LLC - Power Plants and SWOT Analysis, 2018 Update Summary The report contains a detailed description of the power generation company’s business operations, history, corporate strategy, and business structure. This report contains a detailed SWOT analysis, information on key emp …
  • Japan Airlines Co Ltd:企業の戦略・SWOT・財務情報
    Japan Airlines Co Ltd - Strategy, SWOT and Corporate Finance Report Summary Japan Airlines Co Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerin …
  • Tricida Inc (TCDA):製薬・医療:M&Aディール及び事業提携情報
    Summary Tricida Inc (Tricida), formerly Trilypsa Inc is a clinical-stage pharmaceutical and drug discovery company. The company discovers and develops novel non-absorbed therapies for the treatment of renal, metabolic and cardiovascular diseases. Its lead drug candidate TRC101, is under clinical dev …
  • AgaMatrix Inc:医療機器:M&Aディール及び事業提携情報
    Summary AgaMatrix Inc (AgaMatrix) is a medical device company that offers biosensors and blood glucose monitors. The company designs, develops and manufactures diabetes products for pharmaceutical companies. Its products comprise Jazz Wireless 2, blood glucose monitors, Connected Health and AgaMatri …
  • Myriad Genetics Inc (MYGN):医療機器:M&Aディール及び事業提携情報
    Summary Myriad Genetics Inc (Myriad) is a specialty molecular diagnostic company, which discovers and commercializes molecular diagnostic tests, personalized medicine and services for major diseases. The company’s product portfolio includes molecular diagnostic testing products that analyze genes, t …
  • Orix Corporation:企業の戦略・SWOT・財務分析
    Orix Corporation - Strategy, SWOT and Corporate Finance Report Summary Orix Corporation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and cor …
  • JSHP Transformer Co Ltd:企業の戦略的SWOT分析
    JSHP Transformer Co Ltd - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products an …
  • Ascendance Biotechnology Inc-医療機器分野:企業M&A・提携分析
    Summary Ascendance Biotechnology Inc (Ascendance), formerly Hepregen Corp is a healthcare products provider that offers cell based assay products. The company provides vitro micro-liver cell-based platforms for use in safety testing, and pharmaceutical, biotherapeutic and diagnostic product developm …
  • Ingles Markets Inc:企業の戦略・SWOT・財務情報
    Ingles Markets Inc - Strategy, SWOT and Corporate Finance Report Summary Ingles Markets Inc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and …
  • Bashneft (BANE)-石油・ガス分野:企業M&A・提携分析
    Summary Bashneft is a vertically integrated oil and gas company. It operates in the oil and gas production, refining, petrochemical production, marketing and distribution of oil and petroleum products. It sales crude oil, petroleum products and petrochemical products to the domestic market. The comp …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆